Income Statement
ARS PHARMACEUTICALS, INC.
SPRY
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
84.28 | 89.15 | 0.03 | 1.32 | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
84.28 | 89.15 | 0.03 | 1.32 | - |
|
Operating Expenses
|
263.73 | 92.23 | 67.55 | 36.83 | 89.58 |
|
Research & Development
|
13.18 | 19.58 | 20.27 | 18.38 | 61.50 |
|
Selling, General & Administrative
|
230.12 | 71.68 | 47.28 | 18.46 | 28.08 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-179.45 | -3.08 | -67.52 | -35.52 | -89.58 |
|
Non-Operating Income
|
-8.07 | -11.37 | - | 0.83 | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | 0.60 | - |
|
Other Non-Op Income / Expense
|
8.07 | 11.37 | 13.16 | 0.97 | - |
|
Income Before Tax
|
-171.38 | 8.29 | - | - | - |
|
Income Tax Expense
|
-0.08 | 0.29 | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-171.30 | 8.00 | -54.37 | -34.68 | -89.48 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-178.08 | -3.08 | -67.52 | -35.52 | -89.58 |
|
Earnings Per Share (Basic)
|
-1.74 | 0.08 | -0.57 | -0.87 | - |
|
Diluted EPS
|
-1.74 | 0.08 | -0.57 | -0.87 | - |
|
Weighted Average Shares
|
98.57 | 96.94 | 95.22 | 39.96 | - |
|
Diluted Weighted Avg Shares
|
98.57 | 102.39 | 95.22 | 39.96 | - |
|
Comprehensive Income
|
-0.10 | 8.17 | -54.72 | -34.28 | -89.80 |